A “Precedent-Setting” OTC Switch – And A Case Study In Disregarding FDA’s Advice
Executive Summary
FDA urged the Differin OTC switch advisory committee to consider the application as “precedent setting” given the theoretical risk of teratogenicity – but one committee member was more worried about the bad precedent of approving an application for a sponsor that didn’t do a label comprehension study the way FDA requested.
You may also be interested in...
Reinventing OTCs: FDA Seeks New Models; Stakeholders Urge Renewed Focus
FDA convened a two-day hearing to solicit new ideas to replace the OTC drug monograph system as part of a broader look at ways to enhance the regulatory model for OTCs. However, the architects of the process strongly urged FDA not to overhaul the system – but instead focus more attention on it. At stake is whether FDA makes an all out push to increase OTC switches in coming years.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.